AbbVie Inc. (ABBV)
AbbVie Wins FDA Nod for Decnupaz for Rare Blood Cancer Indication
ABBV's Decnupaz wins FDA approval for BPDCN, adding its first blood cancer ADC and a new option for an ultra-rare aggressive malignancy.
How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds?
ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.
Two Paths to Growth: Johnson & Johnson vs AbbVie
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that beat revenue expectations and prompted raised full-year guidance.
The Dividend Stocks That Generate $60,000 Tax-Free Inside a Roth (And What They Cost You in a Taxable Account)
Holding a high-yield dividend portfolio in a taxable account at the 24% federal bracket means writing the IRS a $14,400 check every year on $60,000 of income that should have been yours.
The Dividend Stocks That Can Replace a $65,000 Income and What They'll Cost You
Dividend-growth blue chips like Coca-Cola double income in nine years despite lower starting yields, while high-yield BDCs and REITs with frozen payouts risk delivering less income over a decade than lower-yield growers.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth
ABBV's neuroscience sales jump 26% in Q1, driven by Vraylar, migraine drugs and Botox as new therapies fuel growth.
How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results?
ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.
Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now
Realty Income (
AbbVie Inc. (ABBV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AbbVie Inc. (ABBV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AbbVie's Growth Engine Is Firing On All Cylinders
AbbVie is a compelling 'Buy' as it has strong momentum in existing drugs and has a robust pipeline. Robust Q1 2026 results: net revenue up 12.4% YoY, driven by Immunology (Skyrizi +29%, Rinvoq +20%) and Neuroscience (+24%). Management raised 2026 EPS guidance to $14.18, signaling 42% YoY growth and confidence in ABBV's diversified growth drivers and pipeline.
AbbVie Deserves A Higher Multiple
AbbVie remains a buy as fundamentals strengthen and valuation sits near multiyear lows after recent stock underperformance. Q1 net revenues grew 12.4% YoY, indicating robust overall business activity despite some Immunology portfolio shakiness. Raised full-year 2026 EPS guidance signals management confidence, with underlying EPS growth projected at 14% annually after adjusting for IPR&D and milestone impacts.
